18 and older, any sex, with Chronic Sinusitis or Chronic Rhinosinusitis (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal PolypsPrimary· Week 24
The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. The diary is completed daily by study participants throughout the study. Each symptom is rated on a 4-point (0-3) scale where 0= none/absent symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms. The composite score of 3CS is the sum of the three cardinal symptom scores. The 3CS total score ranges from 0-9, with higher scores indicating worse symptoms.
Group
Value
95% CI
LYR-210
-2.73
± 0.239
Sham Procedure Control
-1.61
± 0.332
CFBL in the 7-day Average Composite Score of 3CS in All Participants at Week 24Secondary· Week 24
The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. The diary is completed daily by study participants throughout the study. Each symptom is rated on a 4-point (0-3) scale where 0= none/absent symptoms, 1=mild symptoms, 2=moderate symptoms, and 3=severe symptoms. The composite score of 3CS is the sum of the three cardinal symptom scores. The 3CS total score ranges from 0-9, with higher scores indicating worse symptoms.
Group
Value
95% CI
LYR-210
-2.62
± 0.229
Sham Procedure Control
-1.72
± 0.305
CFBL in the 22-item Sino-Nasal Outcome Test (SNOT-22) Total Score at Week 24Secondary· Week 24
The SNOT-22 questionnaire is a 22-item disease-specific quality of life instrument. Each symptom is scored on a 6-point scale where 0 = no problem and 5 = problem as bad as it can be. The total SNOT-22 score is the sum of the 22 items and can range from 0 to 110 with higher scores indicating worse symptoms.
Group
Value
95% CI
LYR-210
-22.4
± 2.05
Sham Procedure Control
-13.7
± 2.61
CFBL in the 3-D Volumetric CT Score at Week 20Secondary· Week 20
Change from baseline in the percent opacification of the bilateral anterior and posterior ethmoids at Week 20, as determined by 3-D volumetric CT analysis. 3-D volumetric scoring involves evaluations of each slice of 3-D coronal CT sequences and summing of all the slices to create a volumetric score ranging from 0% to 100%.
A negative change from Baseline indicates improvement from Baseline.
Group
Value
95% CI
LYR-210
-2.70
± 0.962
Sham Procedure Control
-0.55
± 1.271
Rescue Treatment Requirement Through Week 24Secondary· Week 24
Number and percent of participants requiring rescue treatment (systemic corticosteroid for any reason or participants that were recommended/underwent sinonasal surgery) through Week 24.
Group
Value
95% CI
LYR-210
12
Sham Procedure Control
7
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse Events are reported from the time the informed consent form is signed until completion of all follow-up visits, up to Week 24..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
LYR-210
Serious: 2/112 (2%)
Deaths: 0/112
Sham Procedure Control
Serious: 0/60 (0%)
Deaths: 0/60
Serious adverse events (3 terms)
Reaction
System
LYR-210
Sham Procedure Control
Lumbar spinal stenosis
Musculoskeletal and connective tissue disorders
—
—
Colon adenoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lyra Therapeutics
Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05295459.